Umlaut.bio GmbH
tRNA modification inhibition for cancer and inflammation
Umlaut.bio GmbH is a pioneering biotech company focused on developing first-in-biology therapies targeting cancer and inflammatory diseases. Small molecules under development inhibit key steps in tRNA modification thereby preventing overactivation of a multitude of signalling transduction pathways. This is a hallmark of uncontrolled cancer growth as well as autoimmune diseases which can not be addressed with chemotherapy or targeting individual proteins.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
23.03.2026
Umlaut.bio extends pre-seed round to EUR 3 million (startupticker.ch)
19.02.2026
13.05.2025
No Jobs
No videos and documents
No Awards
Umlaut.bio GmbH
tRNA modification inhibition for cancer and inflammation
Website:
umlaut.bio/
Headquarter:
Basel
Foundation Date:
February 2025
Technology:
- Biotech
Sectors:
- Biotech
- Cancer
- Drug discovery
- Inflammation
- Small molecule drugs